Literature DB >> 29224678

Atherosclerosis in systemic lupus erythematosus.

Sara Croca1, Anisur Rahman2.   

Abstract

Cardiovascular disease (CVD), comprising coronary heart disease and stroke, is one of the most important causes of death in patients with systemic lupus erythematosus (SLE). The risks of developing both clinical CVD and sub-clinical atherosclerosis are increased in patients with SLE. This increase is not fully explained by traditional cardiovascular risk factors such as smoking, hypertension and elevated cholesterol, and it is believed that immune dysfunction also contributes to CVD risk in SLE. In particular, recent studies have shown that abnormalities in both serum lipid profile and the autoantibody and T lymphocyte response to lipids may play a role in development of atherosclerosis. The standard CVD risk calculation algorithms based on traditional risk factors underestimate the risk of developing CVD in patients with SLE. Thus, novel algorithms incorporating new biomarkers such as pro-inflammatory high-density lipoprotein and use of imaging techniques such as carotid ultrasound scanning may become increasingly valuable.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Autoantibodies; Cardiovascular disease; Invariant natural killer T cells; Lipids; Risk stratification; Systemic lupus erythematosus

Mesh:

Year:  2017        PMID: 29224678     DOI: 10.1016/j.berh.2017.09.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  11 in total

Review 1.  Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

2.  QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.

Authors:  Shuo-Lin Wang; Wei Li; Tian-Fang Li; Xu Liang; Ye-Lan Yan; Sheng-Yun Liu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Heat-Killed Lactobacillus reuteri GMNL-263 Inhibits Systemic Lupus Erythematosus-Induced Cardiomyopathy in NZB/W F1 Mice.

Authors:  Peng Xiang; Chih-Yang Huang; Yu-Lan Yeh; Min-Chi Lu; Bruce Chi-Kang Tsai; Bor-Show Tzang; Shiu-Min Cheng; Xiaoyong Zhang; Liang-Yo Yang; B Mahalakshmi; Wei-Wen Kuo
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

Review 4.  Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication.

Authors:  Gashaw Dessie; Birhanu Ayelign; Yonas Akalu; Tewodros Shibabaw; Meseret Derbew Molla
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-17       Impact factor: 3.168

5.  Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus.

Authors:  Vignesh Sadras; Michelle A Petri; Steven Richard Jones; Barbara Lee Peterlin; Subroto Chatterjee
Journal:  Lupus Sci Med       Date:  2020-07

6.  Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus.

Authors:  Mónica Vázquez-Del Mercado; Felipe de J Perez-Vazquez; Eduardo Gomez-Bañuelos; Efrain Chavarria-Avila; Arcelia Llamas-García; Karla I Arrona-Rios; Gustavo Ignacio Diaz-Rubio; Sergio Durán-Barragán; Rosa E Navarro-Hernández; Bethel P Jordán-Estrada; Natalia Prado-Bachega; Miguel A A Gonzalez-Beltran; Carlos Ramos-Becerra; Fernando Grover-Paez; David Cardona-Müller; Ernesto G Cardona-Muñoz
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

Review 7.  Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?

Authors:  Elena Bartoloni; Alessia Alunno; Giacomo Cafaro; Valentina Valentini; Onelia Bistoni; Angelo Francesco Bonifacio; Roberto Gerli
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

8.  Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus.

Authors:  Deng-Ho Yang; Pui-Ying Leong; Sung-Kien Sia; Yu-Hsun Wang; James Cheng-Chung Wei
Journal:  J Clin Med       Date:  2019-06-05       Impact factor: 4.241

Review 9.  IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Xiaojie He
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 10.  Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection.

Authors:  Ya Liu; Hai-Gang Zhang
Journal:  Front Med (Lausanne)       Date:  2021-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.